A group of the world's leading drugmakers have joined the U.K.'s ambitious initiative to sequence the genomes of 100,000 Britons, mining the data with hopes of finding new pathways to treat cancer and rare diseases.
The tick-borne parasite that causes East Coast fever kills 1 million cows per year. Now University of Edinburgh scientists are proposing that a vaccine be made from a related--but far less deadly--parasite.
At the American Academy of Orthopedic Surgeons meeting in Las Vegas, Zimmer touted its new training program enabling patients with its new Persona Knee System to be treated in an outpatient setting.
U.K. contractor Ergomed has made Asian landfall, opening an office in Taiwan with eyes on forging traditional CRO deals and signing risk-sharing agreements with drugmakers.
When patients sign up for a clinical trial, how well do they understand the risks, requirements and restrictions that come with it? Icon, a global CRO that handles thousands of studies a year, is working with behavioral scientists at Carnegie Mellon University to study how investigators can improve the informed consent process.
With Sun Pharmaceutical's $4 billion buyout of Ranbaxy Laboratories all but wrapped up, the combined company has plenty on its plate: get plants banned by the FDA in order, get more products approved and to the market and find $250 million in savings with minimal layoffs.
Harvard professor Doug Melton is having quite a week. His work on potential cell therapies for diabetes just fueled the launch of a well-funded biotech startup, and now he's signed up with AstraZeneca to help the drugmaker spotlight new treatments for the disease.
As Big Pharma casts an eye toward med tech to diversify its offerings and capitalize on a growing market, Novartis is jumping on the bandwagon with new digital and patient monitoring devices.
GlaxoSmithKline is looking for some new partners in academia, launching a contest for would-be collaborators with early-stage projects that could translate into marketable medicines.
Novartis CEO Joseph Jimenez presides over one of the industry's largest R&D budgets, committing about $10 billion a year to drug development. But the American-born executive, in contrast to his predecessor, has made a habit of ditching projects when they start to look futile, a philosophy that trickles down to Novartis' lab work.